Section Arrow
CRDF.NASDAQ
- Cardiff Oncology
Quotes are at least 15-min delayed:2026/08/31 09:33 EDT
Regular Hours
Last
 0.9545
+0.0145 (+1.54%)
Day High 
0.9545 
Prev. Close
0.94 
1-M High
1.13 
Volume 
7.31K 
Bid
0.9401
Ask
0.9689
Day Low
0.9401 
Open
0.9401 
1-M Low
0.7566 
Market Cap 
73.13M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.94 
20-SMA 0.96 
50-SMA 1.04 
52-W High 3.31 
52-W Low 0.7566 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.60/-0.57
Enterprise Value
73.23M
Balance Sheet
Book Value Per Share
0.34
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
593.00K
Operating Revenue Per Share
0.01
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
AIMAIM ImmunoTech Inc.0.3342+0.0758+29.33%-- 
MRNAModerna136.34-1.65-1.20%-- 
SLSSELLAS Life Sciences Group13.135-0.075-0.57%-- 
IOVAIovance Biotherapeutics7.8201-0.1899-2.37%-- 
ARTLArtelo Biosciences Inc5.55-0.4143-6.95%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigationin other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.